Bruton tyrosine kinase inhibitor
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Bruton tyrosine kinase inhibitor, covering 2025-08-13 to 2026-03-30. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies [Phase 2]